Sandoz Inc, a global company involved in generic pharmaceuticals and biosimilars, in collaboration with Kit Check Inc, a company involved in automated medication management solutions for hospitals, is offering its first two injectable medicines with Radio Frequency Identification (RFID) to United States hospitals this month, it was reported Thursday.
The medicines include Anectine 200mg/10mL and Rocuronium 50mg/5mL and 10mg/5mL (paralytics to relax muscles during surgery or other medical procedures). Several more Sandoz medicines are likely to be offered to Kit Check's hospital partners during early 2021.
Sandoz says that it is helping hospital pharmacies to improve efficiency, decrease risk and better support patient treatment in hospitals by offering real-time inventory reports and timely tracking of expiration of products and recalls via its collaboration with Kit Check. This will aid in automatic replenishment of supplies long-term.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules